Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | SIRT2 | Q8IXJ6 | 7/20 | 0.51 |
| ▸ | ALB | P02768 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6359077 | 0.89 | ALB (0.56) | APEX1SMN1; SMN2LMNAPOLBALB | |
| SCHEMBL6352948 | 0.85 | APEX1 (0.63) | APEX1SMN1; SMN2LMNAPOLBSIRT2 | |
| SCHEMBL6352310 | 0.84 | APEX1 (0.52) | APEX1SMN1; SMN2LMNAPOLBSIRT2 | |
| SCHEMBL6353472 | 0.84 | APEX1 (0.56) | APEX1SMN1; SMN2LMNAPOLBSIRT2 | |
| SCHEMBL6357082 | 0.84 | APEX1 (0.56) | APEX1SMN1; SMN2LMNAPOLBSIRT2 | |
| SCHEMBL6349541 | 0.83 | SIRT2 (0.51) | APEX1SMN1; SMN2LMNAPOLBSIRT2 | |
| SCHEMBL6352026 | 0.83 | SIRT2 (0.51) | APEX1SMN1; SMN2LMNAPOLBSIRT2 | |
| SCHEMBL6357891 | 0.83 | APEX1 (0.51) | APEX1SMN1; SMN2LMNAPOLBSIRT2 | |
| SCHEMBL6352847 | 0.82 | SIRT2 (0.52) | APEX1SMN1; SMN2LMNAPOLBSIRT2 | |
| SCHEMBL6352574 | 0.82 | APEX1 (0.54) | APEX1SMN1; SMN2LMNAPOLBSIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113450-A1 | Antibacterial agents | PHARMACIA & UPJOHN COMPANY | 2005-05-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113450-A1 | Antibacterial agents | CLPP, SPOUT1, SAMHD1 | APEX1 502/4885SMN1; SMN2 3015/4885LMNA 4552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.